CSIMarket
 


Rocket Pharmaceuticals Inc   (RCKT)
Other Ticker:  
 

Rocket Pharmaceuticals Inc 's Working Capital Ratio

RCKT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Rocket Pharmaceuticals Inc 's Current Assets grew by 43.19 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Rocket Pharmaceuticals Inc 's Working Capital Ratio to 13.35, Working Capital Ratio remained below Rocket Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Working Capital Ratio than Rocket Pharmaceuticals Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 287, from total ranking in the second quarter 2023 at 531.

Explain Working Capital Ratio
How much in Current Assets RCKT´s has?
What is the value of RCKT´s Current Liabilities?


RCKT Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 10.92 % 41.41 % 38.26 % 76.7 % 23.24 %
Y / Y Current Assets Change 43.63 % -4.2 % -4.47 % -7.14 % -26.8 %
Working Capital Ratio MRQ 13.35 9.09 10.83 9.29 10.31
RCKT's Total Ranking # 287 # 531 # 477 # 190 # 416
Seq. Current Liabilities Change -2.53 % 10.06 % -20.33 % 29.78 % 24.26 %
Seq. Current Assets Change 43.19 % -7.68 % -7.15 % 17.01 % -4.49 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 128
Overall Market # 287


Working Capital Ratio Statistics
High Average Low
38.81 18.06 7.3
(Mar 31 2018)   (Sep 30 2020)




Financial Statements
Rocket Pharmaceuticals Inc 's Current Liabilities $ 33 Millions Visit RCKT's Balance sheet
Rocket Pharmaceuticals Inc 's Current Assets $ 447 Millions Visit RCKT's Balance sheet
Source of RCKT's Sales Visit RCKT's Sales by Geography


Cumulative Rocket Pharmaceuticals Inc 's Working Capital Ratio

RCKT's Working Capital Ratio for the trailling 12 Months

RCKT Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 10.92 % 41.41 % 38.26 % 76.7 % 23.24 %
Y / Y Current Assets TTM Growth 43.63 % -4.2 % -4.47 % -7.14 % -26.8 %
Working Capital Ratio TTM 10.57 9.82 10.73 11.66 13.94
Total Ranking TTM # 3599 # 333 # 284 # 87 # 255
Seq. Current Liabilities TTM Growth -2.53 % 10.06 % -20.33 % 29.78 % 24.26 %
Seq. Current Assets TTM Growth 43.19 % -7.68 % -7.15 % 17.01 % -4.49 %


On the trailing twelve months basis RCKT Current Assets soared by 43.63 % in III Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in Rocket Pharmaceuticals Inc 's Working Capital Ratio to 10.57, Working Capital Ratio remained below RCKT average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 465 other companies have achieved higher Working Capital Ratio than Rocket Pharmaceuticals Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 333 to 3599.

Explain Working Capital Ratio
How much in Current Assets RCKT´s has?
What is the value of RCKT´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 466
Healthcare Sector # 965
Within the Market # 3599


trailing twelve months Working Capital Ratio Statistics
High Average Low
26.03 14.89 9.82
(Mar 31 2018)   (Jun 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Rayzebio Inc   34.39 $ 544.986  Millions$ 15.847  Millions
Cymabay Therapeutics Inc   32.37 $ 447.659  Millions$ 13.831  Millions
Verona Pharma Plc  32.02 $ 276.527  Millions$ 8.636  Millions
Atea Pharmaceuticals Inc   31.93 $ 603.316  Millions$ 18.893  Millions
Greenwich Lifesciences Inc   30.76 $ 9.144  Millions$ 0.297  Millions
Theseus Pharmaceuticals Inc   29.93 $ 209.586  Millions$ 7.003  Millions
Aprea Therapeutics Inc   29.72 $ 25.640  Millions$ 0.863  Millions
Viking Therapeutics Inc   29.14 $ 381.300  Millions$ 13.086  Millions
Atossa Therapeutics Inc   28.35 $ 97.648  Millions$ 3.444  Millions
Karuna Therapeutics Inc   27.88 $ 1,365.397  Millions$ 48.968  Millions
Disc Medicine Inc   25.96 $ 374.263  Millions$ 14.416  Millions
Belite Bio Inc  24.76 $ 89.940  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.55 $ 355.195  Millions$ 14.471  Millions
Gh Research Plc  24.49 $ 164.089  Millions$ 6.701  Millions
Bright Minds Biosciences Inc   24.26 $ 5.218  Millions$ 0.215  Millions
Design Therapeutics Inc   23.77 $ 294.543  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.67 $ 5.235  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.91 $ 47.886  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.38 $ 270.455  Millions$ 12.087  Millions
Tyra Biosciences Inc   22.14 $ 224.630  Millions$ 10.147  Millions
Cyteir Therapeutics Inc   21.89 $ 130.643  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.87 $ 244.466  Millions$ 11.180  Millions
Eledon Pharmaceuticals Inc   21.73 $ 62.991  Millions$ 2.899  Millions
Astria Therapeutics inc   21.53 $ 191.466  Millions$ 8.894  Millions
Xenon Pharmaceuticals Inc   21.46 $ 531.008  Millions$ 24.744  Millions
Sagimet Biosciences inc   20.79 $ 102.816  Millions$ 4.946  Millions
Acasti Pharma Inc   20.68 $ 28.887  Millions$ 1.397  Millions
Akero Therapeutics Inc   20.25 $ 575.979  Millions$ 28.447  Millions
Tenax Therapeutics Inc   19.73 $ 11.883  Millions$ 0.602  Millions
Mineralys Therapeutics Inc   19.59 $ 265.375  Millions$ 13.543  Millions

Date modified: 2023-11-08T18:20:41+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com